The Phase I study is being conducted in the US and Israel with two patient subgroups — stratum I, which includes patients with chronic nerve atrophy and began dosing in March; and stratum II, which is enrolling patients with recent onset of NAION.
The siRNAs inhibited tumor necrosis factor-alpha, a pro-inflammatory cytokine implicated in a variety of inflammatory diseases, in the animals' colons and protected against ulcerative colitis, according to the paper.
The company noted that since it develops LNP formulations individually for each of its drug candidates, the delay in TKM-apoB will have "no impact" on any of its other drug programs or those of its collaboration partners, who include Roche and Pfizer.
The collaboration brings together Ariadne, Cellecta, and the Roswell Park Cancer Institute to develop "a better understanding of the mechanisms of prostate cancer that result in novel targets and biomarkers."
Last week, EGEN said it had extended a collaboration with SurModics to develop a controlled-release system for siRNA delivery. As with its other programs, the company plans to let the delivery route determine the indications it pursues.